This platform integrates three modules: a PD-L1 aptamer for selective tumor recognition; auranofin (AUR) as a radiosensitizer to amplify radiation-induced immunogenic cell death; and a multivariate-gated aptamer assembly (ACP) responsive to ATP and MMP-2 signals in the tumor microenvironment, enabling controlled release of the immunostimulatory agent eCpG. The gene discussed is MMP2; the disease is neoplasm.